Every person who receives a diagnosis of myelodysplastic syndromes arrives at a crossroads, asking which path will actually help, and for a long time medicine could offer only educated guesses. Researchers at Sylvester Comprehensive Cancer Center and the University of Miami Miller School of Medicine now suggest that the answer may already be written in the chemical marks on a patient's DNA when the disease is first identified. Their work, published in the Journal of Clinical Investigation, points toward a future in which the epigenetic character of a patient's illness helps guide the choice of
DNA Methylation Patterns at Diagnosis May Help Predict Which MDS Patients Respond to Azacitidine
Which treatment is most likely to work for me?
Mark
So what's actually new here? Doctors already know methylation matters in MDS.
Mimi
They do, and the drugs target it. What's been missing is a way to tell at diagnosis who will respond. This study built models from methylation, gene activity, mutations and clinical information to try to do that.
Mark
And methylation did better than gene activity alone?
Mimi
Yes. Some of the strongest signals came from regulatory regions of DNA that researchers haven't traditionally focused on.
Luke
Let me slow us down. How many patients are we talking about?
Mimi
98 patients, with the models tested in an independent group.
Luke
That's a modest sample, and the source doesn't say how large the independent group was or how well the models performed overall. We have no accuracy figure.
Mark
What about the 71% number?
Mimi
That's Cluster VI, the group with relatively few mutations. Seventy-one percent of those patients responded to azacitidine.
Luke
Which is striking, but it's one cluster out of seven. We aren't told the response rates in the others or how many patients sat in Cluster VI, so I'd not read it as a headline rate for MDS.
Mark
So is this ready for clinics?
Mimi
No. Sekeres says plainly that more research is needed before it guides routine care.
Luke
Agreed. It's a step, not a test a patient can get today.
El Pulso
- A newly diagnosed patient faces a high-stakes choice with no reliable way to know whether the standard drug will work.
- Researchers examined mutations, methylation marks and gene activity in 98 patients, then tested their predictive models on a separate group.
- Seven distinct biological clusters emerged, and Cluster VI, with few DNA mutations, saw 71% of patients respond to azacitidine.
- Methylation signals outperformed gene activity alone, pointing to regulatory regions of DNA that were previously overlooked.
- The findings remain a promising model still awaiting confirmation before they can shape routine treatment decisions.
Every person who receives a diagnosis of myelodysplastic syndromes arrives at a crossroads, asking which path will actually help, and for a long time medicine could offer only educated guesses. Researchers at Sylvester Comprehensive Cancer Center and the University of Miami Miller School of Medicine now suggest that the answer may already be written in the chemical marks on a patient's DNA when the disease is first identified. Their work, published in the Journal of Clinical Investigation, points toward a future in which the epigenetic character of a patient's illness helps guide the choice of a standard drug, azacitidine, though the path from promising signal to everyday practice is still being walked.
A patient newly diagnosed with myelodysplastic syndromes, a group of disorders in which the bone marrow struggles to produce healthy blood cells, must choose a treatment. For years, doctors have lacked a dependable way to tell who will respond to azacitidine, a primary drug for the condition. A multicenter study published in the Journal of Clinical Investigation, led in part by researchers at Sylvester Comprehensive Cancer Center, suggests the clues may already be present at diagnosis.
The team focused on methylation, the chemical marks on DNA that switch genes on or off without changing the sequence itself. They analyzed mutations, methylation and gene activity in 98 patients, grouped them by their patterns, built predictive models and tested those models on an independent set of patients, alongside clinical information. The analysis revealed seven biological groups. One, Cluster VI, carried relatively few DNA mutations, and 71% of its patients responded to azacitidine.
Methylation proved more informative than gene activity alone, with some of the strongest signals arising from regulatory regions of DNA that researchers had not traditionally emphasized. Dr. Maria Figueroa framed the goal around the patient's own question: which treatment is most likely to work for me? First author Qin Yang described the effort as an attempt to capture a fuller picture of the disease. Dr. Mikkael Sekeres called advance knowledge of therapy response one of the holy grails of cancer care, while cautioning that more research is required before the findings guide routine practice.
For now, the study offers a promising model rather than a clinical tool, but it hints at a future where treatment decisions at diagnosis rest on a deeper understanding of each patient's disease.
A patient diagnosed with myelodysplastic syndromes, a group of disorders in which the bone marrow fails to make healthy blood cells normally, faces a decision at the start: which treatment? For years, doctors have had no dependable way to say whether a given patient will respond to the standard drug. A new multicenter study suggests the answer may already be sitting in the patient's cells at the time of diagnosis.
The study, published in the Journal of Clinical Investigation, involved researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine. It found that patterns of DNA methylation present at diagnosis could help predict which patients will respond to azacitidine, a primary therapy for MDS.
Methylation refers to chemical marks on DNA that help switch genes on or off without altering the DNA sequence itself. Altered methylation is a hallmark of MDS, and drugs known as DNA methyltransferase inhibitors are used to treat it. Azacitidine is one of them. Yet reliable biomarkers of who will benefit from these drugs have been lacking.
The team examined DNA mutations, methylation marks and gene activity in 98 patients with MDS. They sorted the patients into groups based on methylation patterns, built computer models to predict response to azacitidine, and then tested those models in an independent group of patients. They also folded in clinical information alongside the molecular data.
The analysis produced seven groups with distinct biological features. One of them, labeled Cluster VI, was marked by relatively few DNA mutations. In that group, 71% of patients responded to azacitidine.
Methylation proved more useful than gene activity alone for predicting response. Some of the strongest predictive signals came from regulatory regions of DNA, beyond the parts researchers have traditionally concentrated on.
Maria "Ken" Figueroa, M.D., a Sylvester researcher, associate director of translational research and co-lead of the study, framed the aim in terms of the patient's own question at diagnosis: which treatment is most likely to work for me? She said the epigenetic features of the disease could supply information that conventional approaches have not captured. First author Qin Yang, Ph.D., an assistant scientist at the Miller School, said the group set out to capture a fuller picture of the disease and to understand which features separate responders from non-responders.
Mikkael Sekeres, M.D., M.S., chief and professor of hematology at Sylvester and the study's other co-lead, called knowing whether a therapy will work before starting it one of the holy grails of cancer treatment. He was careful about the limits: more research is needed before the findings can guide routine care. He described the work as a step toward more informed treatment decisions, and said the goal is to turn a better understanding of MDS into guidance that lets patients face treatment with greater confidence.
The next stage is further research. Until the findings are confirmed and refined, they remain a promising model rather than a tool for the clinic.
Citas Notables
Our goal is to get closer to answering one of the most important questions for a patient at diagnosis: Which treatment is most likely to work for me?— Maria "Ken" Figueroa, M.D., Sylvester Comprehensive Cancer Center
More research is needed before the findings can guide routine care, but they offer a step toward more informed treatment decisions.— Mikkael Sekeres, M.D., M.S., Sylvester Comprehensive Cancer Center (paraphrased)
Quieres la nota completa?
Lee el original en News-Medical ↗